Evidence map›Paper›PMID 30703064›Full record

ArticleEndocrinology, diabetes & metabolism case reports2019

Hypercalcitoninaemia in pseudohypo-parathyroidism type 1A and type 1B.

Maria P Yavropoulou, Efstathios Chronopoulos, George Trovas, Emmanouil Avramidis, Francesca Marta Elli, Giovanna Mantovani, Pantelis Zebekakis, John G Yovos

Open access · goldAbstract read
In one paragraph

Article in Endocrinology, diabetes & metabolism case reports, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.9field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Review
  3. Parental Origin ofJBMR plus · 2022
    Article
  4. "Holidays" for osteoporosis drugs: A case-based approach.Case reports in women's health · 2019
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 6 institutions in 2 countries.

Maria P Yavropoulou1st Propaedeutic Department of Internal Medicine, LAIKO General Hospital of Athens.
Efstathios Chronopoulos2nd Orthopaedic Department, Konstantopouleio General Hospital.
George TrovasLaboratory for Research of the Musculoskeletal System, Th Garofalidis, National and Kapodistrian University of Athens, Athens, Greece.
Emmanouil Avramidis2nd Orthopaedic Department, Konstantopouleio General Hospital.
Francesca Marta ElliEndocrinology Unit, Department of Clinical Sciences and Community Health, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, University of Milan, Milan, Italy.
Giovanna MantovaniEndocrinology Unit, Department of Clinical Sciences and Community Health, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, University of Milan, Milan, Italy.
Pantelis Zebekakis1st Department of Internal Medicine, AHEPA University Hospital, Thessaloniki, Greece.
John G Yovos1st Department of Internal Medicine, AHEPA University Hospital, Thessaloniki, Greece.
Agia Olga Hospital · GRAHEPA University Hospital · GRFondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico · ITLaiko General Hospital of Athens · GRNational and Kapodistrian University of Athens · GRUniversity of Milan · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Pseudohypoparathyroidism (PHP) is a heterogeneous group of rare endocrine disorders characterised by normal renal function and renal resistance to the action of the parathyroid hormone. Type 1A (PHP1A), which is the most common variant, also include developmental and skeletal defects named as Albright hereditary osteodystrophy (AHO). We present two cases, a 54- and a 33-year-old male diagnosed with PHP who were referred to us for persistently high levels of serum calcitonin. AHO and multinodular goitre were present in the 54-year-old male, while the second patient was free of skeletal deformities and his thyroid gland was of normal size and without nodular appearance. We performed GNAS molecular analysis (methylation status and copy number analysis by MS-MLPA) in genomic DNA samples for both patients. The analysis revealed a novel missense variant c.131T>G p.(Leu44Pro) affecting GNAS exon 1, in the patient with the clinical diagnosis of PHP1A. This amino acid change appears to be in accordance with the clinical diagnosis of the patient. The genomic DNA analysis of the second patient revealed the presence of the recurrent 3-kb deletion affecting the imprinting control region localised in the STX16 region associated with the loss of methylation (LOM) at the GNAS A/B differentially methylated region and consistent with the diagnosis of an autosomal dominant form of PHP type 1B (PHP1B). In conclusion, hypercalcitoninaemia may be encountered in PHP1A and PHP1B even in the absence of thyroid pathology. Learning points: We describe a novel missense variant c.131T>G p.(Leu44Pro) affecting GNAS exon 1 as the cause of PHP1A. Hypercalcitoninaemia in PHP1A is considered an associated resistance to calcitonin, as suggested by the generalised impairment of Gsα-mediated hormone signalling. GNAS methylation defects, as in type PHP1B, without thyroid pathology can also present with hypercalcitoninaemia.

Indexed as

2019AdultBoneBrachydactylyCalcitoninCalcium gluconateCalcium (serum)Calcium (urine)Facies - moonFatigueFine needle aspiration biopsyGoitreGreeceHeadacheInsight into disease pathogenesis or mechanism of therapyJanuaryLevothyroxineMaleMolecular genetic analysisMyasthaeniaObesityOsteopeniaParathyroidPentagastrinPhosphate (serum)PseudohypoparathyroidismPTHShort statureSkeletal deformityTetanyThyroid antibodiesThyroidectomyUltrasound scanUric acid (blood)Vitamin DWhiteX-ray

Identifiers

PMID30703064
PMCPMC6365682
OpenAlexW2914372526

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.